Amgen strikes Enbrel 'outcomes' contract with Harvard Pilgrim as biosimilar competition loom

FiercePharma ----- Biosimilar competition for Amgen’s blockbuster rheumatoid arthritis drug Enbrel is lurking in the background, but the biotech may have found a way to help blunt the impact with outcomes-based contracts for the popular med. Amgen and Harvard Pilgrim Healthcare today announced a two-year contract in which the insurer will pay less for the drug if patients score below certain levels based on six criteria that will be measured and then crunched by “an effectiveness algorithm.” The measurements include patient compliance, switching or adding drugs, dose escalation and steroid interventions. To learn more about Amgen strikes Enbrel 'outcomes' contract with Harvard Pilgrim as biosimilar competition looms click on the picture below to read more.